Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy

BACKGROUND: CD19 chimeric antigen receptor T cell (CD19CAR-T) has shown great potential to treat acute B cell lymphoblastic leukemia (B-ALL) and B cell lymphoma, and most of anti-CD19 scFv are derived from murine antibody sequences. However, about 10–20% of B-ALL patients exhibit primary resistance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Wang, Kai, Zhao, Yu, Wang, Xuan, Wang, Bin, Qin, Maoquan, Zhu, Guanghua, Wu, Huantong, Liu, Zhongfeng, Zheng, Xueling, Zheng, Huyong, Chen, Zhiguo
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7786099/
https://ncbi.nlm.nih.gov/pubmed/33424835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.581116
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars